Clinical trialNCT00915083CompletedPhase 1Interventional

A Phase I Study to Assess the Safety, Pharmacokinetics, and Potential Effects of Amrubicin on the QT/QTc Interval in Cancer Patients With Advanced Solid Tumors.

SponsorCelgeneEnrollment24Advanced Solid Tumors

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

The purpose of the study is to determine whether amrubicin is safe and effective in the treatment of patients with advanced solid tumors. The study will assess the pharmacokinetics of the amrubicin and if it has an effect on the heart.

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

Markus Renschler, MD
Celgene Corporation
Study Director
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

8 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States

University of California San Diego
La Jolla, California, United States
Sarcoma Oncology Center
Santa Monica, California, United States
Indiana University Cancer Pavilion
Indianapolis, Indiana, United States
James Graham Brown Cancer Center
Louisville, Kentucky, United States
Sinai Hospital of Baltimore- Alvin and Lois Lapidus Cancer Institute
Baltimore, Maryland, United States
Montefiore Medical Center
The Bronx, New York, United States
Ut Health Science Center at San Antonio- Cancer Therapy and Research Center
San Antonio, Texas, United States
Hunstman Cancer Institute
Salt Lake City, Utah, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Amrubicin

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 1 Jun 2009
Primary completion: 1 May 2011
Completion: 1 May 2011
Last update posted: 1 Nov 2019
Registered enrollment: 24
Registry id: NCT00915083

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.